Korro Bio, Inc. financial data

Symbol
KRRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
60 First Street, 2 Nd Floor, Suite 250, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Frequency Therapeutics, Inc. (to 11/6/2023)
Latest financial report
10-K - Q4 2024 - Mar 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.14K % +104%
Return On Equity -48.5 % -135%
Return On Assets -36.4 % +49.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.39M shares +17%
Common Stock, Shares, Outstanding 9.38M shares +17%
Entity Public Float 237M USD +1849%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 8.92M shares +483%
Weighted Average Number of Shares Outstanding, Diluted 8.92M shares +483%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 63.6M USD +11.2%
General and Administrative Expense 30.5M USD +12%
Operating Income (Loss) -91.9M USD -8.73%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -83.4M USD -2.83%
Income Tax Expense (Benefit) 141K USD +422%
Net Income (Loss) Attributable to Parent -83.6M USD -2.97%
Earnings Per Share, Basic -9.37 USD/shares +82.3%
Earnings Per Share, Diluted -9.37 USD/shares +82.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.6M USD -66.5%
Marketable Securities, Current 70.5M USD
Assets, Current 132M USD -23.9%
Property, Plant and Equipment, Net 27.7M USD +76.9%
Operating Lease, Right-of-Use Asset 23.8M USD -12.2%
Other Assets, Noncurrent 2.8M USD +3.06%
Assets 226M USD +2.07%
Accounts Payable, Current 3.99M USD -45.2%
Employee-related Liabilities, Current 1.87M USD -43.8%
Accrued Liabilities, Current 6.17M USD -39.6%
Liabilities, Current 15M USD -23.2%
Operating Lease, Liability, Noncurrent 43.5M USD +39.3%
Other Liabilities, Noncurrent 1.47M USD +39.8%
Liabilities 65.8M USD +27.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 268K USD
Retained Earnings (Accumulated Deficit) -267M USD -45.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 160M USD -5.59%
Liabilities and Equity 226M USD +2.07%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.9M USD -11.2%
Net Cash Provided by (Used in) Financing Activities 139K USD -99.7%
Net Cash Provided by (Used in) Investing Activities -5.61M USD -136%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 9.38M shares +17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.4M USD -166%
Deferred Tax Assets, Valuation Allowance 168M USD +15.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 179M USD +16.4%
Operating Lease, Liability 44.8M USD +34.8%
Depreciation 3.55M USD +36.7%
Payments to Acquire Property, Plant, and Equipment 5.61M USD +271%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.4M USD -10.6%
Lessee, Operating Lease, Liability, to be Paid 73.6M USD +10.8%
Property, Plant and Equipment, Gross 35M USD +49.1%
Operating Lease, Liability, Current 1.28M USD -35.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.34M USD +17.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.22M USD -13.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.9M USD -13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.56M USD +2.94%
Deferred Tax Assets, Operating Loss Carryforwards 94.2M USD +17.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.78M USD +2.92%
Additional Paid in Capital 427M USD +20.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 10.3M USD +33.9%
Share-based Payment Arrangement, Expense 4.46M USD +87.4%
Interest Expense 596K USD -28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%